BiotechTube

Tafamidis 61 milligrams

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Transthyretin Amyloid Cardiomyopathy

Conditions

Transthyretin Amyloid Cardiomyopathy

Trial Timeline

Mar 19, 2024 → Oct 13, 2025

NCT ID
NCT06321523

About Tafamidis 61 milligrams

Tafamidis 61 milligrams is a pre-clinical stage product being developed by Pfizer for Transthyretin Amyloid Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT06321523. Target conditions include Transthyretin Amyloid Cardiomyopathy.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT06321523Pre-clinicalCompleted

Competing Products

20 competing products in Transthyretin Amyloid Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
23
EplontersenAstraZenecaPhase 3
77
Eplontersen + PlaceboAstraZenecaPhase 3
77
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3
76
NNC6019-0001Novo NordiskPhase 2
51
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 2
51
CoramitugNovo NordiskPhase 1
32
TafamidisPfizerPre-clinical
22
TafamidisPfizerPre-clinical
22
tafamidis megluminePfizerApproved
84
Fx-1006APfizerPhase 2
51
TafamidisPfizerPhase 3
76
Treatment for TTR amyloidosis + Treatment for TTR amyloidosisPfizerPre-clinical
22
VyndaqelPfizerPre-clinical
22
tafamidisPfizerPhase 3
76
TafamidisPfizerApproved
84
TafamidisPfizerPre-clinical
22
Vyndamax (tafamidis 61mg)PfizerPre-clinical
22

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84